It is Pharma Time: Why Merck and Lilly Stock Are Buys, but not Pfizer.
My 2023 biotech outlook calls for ongoing momentum in title variations. I just will need to determine out what the ...
Read moreDetails
Tag: PFE
Why Pfizer Is Pulling Back again on Exploration Into Unusual Condition, Gene Treatment
Pfizer is preparing to pull again on early-phase research into treatments for exceptional illnesses, which include the development of new ...
Read moreDetails
6 Defensive Health care Stocks for 2023
As buyers confront another uncertain year for public equities, huge-cap health care stocks remain an beautiful defensive perform. They give ...
Read moreDetails
Microsoft Tops the Finest-Managed Providers of 2022
Journal Studies: LeadershipHow the Administration Prime 250 Rankings Are PickedDecember 11, 2022 at 2:01 PM ETThe Drucker Institute’s methodology for ...
Read moreDetails
The 7 Companies That Do It All Well in the Rankings of Very best-Managed Organizations
Journal Stories: ManagementAmong the Very best-Managed Businesses of 2022, Some Warning SignsBy Chris KornelisDecember 11, 2022 at 2:08 PM ETThese ...
Read moreDetails
Horizon Therapeutics Fields Takeover Desire From Pharma Giants
Horizon Therapeutics Fields Takeover Fascination From Pharma Giants
Read moreDetails
Bye-Bye, Bear Market? The Worst Could Be More than for Stocks.
Bye-Bye, Bear Sector? The Worst Could Be In excess of for Shares.
Read moreDetails
Alphabet and Pfizer Inventory Glance Like Buys, States This Longtime Market place Maven
Joe Rosenberg’s connection with Barron’s goes back again to 1963, when he wrote a bullish posting on Trans Earth Airways ...
Read moreDetails
Pfizer’s COVID-19 antiviral Paxlovid brought in $7.5 billion in sales in Q3
Pfizer Inc.'s PFE, -1.86% COVID-19 antiviral Paxlovid brought in $7.5 billion in revenue in the 3rd quarter of the year, ...
Read moreDetails
Pfizer’s Earnings Are Tuesday. What to Enjoy.
Pfizer is set to report its earnings on Tuesday, a week and a 50 % soon after an govt explained ...
Read moreDetails
